Clinical trials: Relapsed Neuroblastoma
Neuroblastoma, Relapsed Neuroblastoma
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
- Conditions
- Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
- Trial name
- NCT04023331
- Testing
- 67Cu-SARTATE, 64Cu-SARTATE
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB)
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
The goal of this clinical trial is to assess safety and efficacy of systemic injection of allogenic NK cells in patients with refractory/recurrent high-risk neuroblastoma.
- Conditions
- Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB), Neuroblastoma in Children
- Trial name
- NCT06674265
- Testing
- Allogenic NK cells infusion
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Marzieh Ebrahimi
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Relapsed or Refractory Neuroblastoma
Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children
This single-arm, multicenter clinical study will treat the patient who have relapsed or refractory neuroblastoma with an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen…
- Trial name
- NCT02919046
- Testing
- GD2-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 22 people
- Sponsor
- Sinobioway Cell Therapy Co., Ltd.
Neuroblastoma
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
This is a Phase I/II study to assess the efficacy and safety of ribociclib in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory (r/r) neuroblastoma (NB), and other solid tumors…
- Trial name
- NCT05429502
- Testing
- Topotecan, Temozolomide, Ribociclib
- Where
- 6 sites in United States, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals